The comparison of 1988 and 2009 FIGO staging system for uterine sarcoma in King Chulalongkorn Memorial Hospital during 1999-2008

1. D’Angelo E, Prat J. Uterine sarcoma: a review. Gynecol Oncol. 2010; 116:131-9.10.1016/j.ygyno.2009.09.023Open DOISearch in Google Scholar

2. Wilailak S, Tansuttiwong A, Tangtrakul S. Uterine sarcomas in Ramathibodi hospital (1987-1998). Thai J Obstet Gynecol. 2000; 12:241-6.Search in Google Scholar

3. Tavassoli FA, Davilee P, eds. World Health Organization classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.Search in Google Scholar

4. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009; 104:179.10.1016/j.ijgo.2008.12.009Search in Google Scholar

5. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009; 105:103-4.10.1016/j.ijgo.2009.02.012Search in Google Scholar

6. Sandra EB, Min Z, Timonthy C, Claudia RB. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gyneoncol Oncol. 2004; 93:204-8.10.1016/j.ygyno.2003.12.029Search in Google Scholar

7. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12:687-90.10.1046/j.1525-1438.2002.01151.xOpen DOISearch in Google Scholar

8. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008; 134:1277-87.10.1007/s00432-008-0422-2Search in Google Scholar

9. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki university central hospital 1990-2001. Gynecol Oncol. 2008; 111: 74-81.10.1016/j.ygyno.2008.06.002Open DOISearch in Google Scholar

10. Sutton G, Kavanagh J, Wolfson A, Tornos C. Corpus: mesenchymal tumors. In: Hoskin WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 873-94.Search in Google Scholar

11. Meredith RF, Elsert DR, Kaka Z, Hodgson SE, Johnston GA, Boutselis JG. An excess of uterine sarcomas after pelvic radiation. Cancer. 1986; 58:2003-7.10.1002/1097-0142(19861101)58:9<2003::AID-CNCR2820580908>3.0.CO;2-2Open DOISearch in Google Scholar

12. Lavie O, Barnett O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008; 18:352-6.10.1111/j.1525-1438.2007.01025.xOpen DOISearch in Google Scholar

13. Buchanan EM, Weinstein LC, Hillson C. Endometrial Cancer. Am Fam Physician. 2009; 80:1075-80.Search in Google Scholar

14. Sirisabya N, Manchana T, Worasethsin P, Khemapech N, Lertkhachonsuk R, Sittisomwong T, et al . Is complete surgical staging necessary in clinically early stage endometrial carcinoma? Int J Gynecol Cancer. 2009; 19: 1057-61.10.1111/IGC.0b013e3181a8ba85Open DOISearch in Google Scholar

15. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer staging systems. J Clin Oncol. 2009; 27:2066-72.10.1200/JCO.2008.19.8366Open DOISearch in Google Scholar

16. Raut CP, Nucci MR, Wang Q, Manolac J, Bertagnollia MM, Demetrid GD, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009; 45:2818-24.10.1016/j.ejca.2009.06.030Open DOISearch in Google Scholar

17. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009; 10:1188-98.10.1016/S1470-2045(09)70226-8Open DOISearch in Google Scholar

18. Nam JH, Park JY. Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol. 2010; 22:36-42.10.1097/GCO.0b013e328334d90f19923988Open DOISearch in Google Scholar

19. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112:820-30.10.1002/cncr.2324518189292Open DOISearch in Google Scholar

20. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based study. Br J Cancer. 2008; 99:1210-15.10.1038/sj.bjc.6604527257050318813312Open DOISearch in Google Scholar

21. Amant F, De Knijf A, Van Calster B, Leunen1 K, Neven1 P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007; 9:1194-9.10.1038/sj.bjc.6603986236046617895898Search in Google Scholar

22. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Onco.l 2008; 111:82-8.10.1016/j.ygyno.2008.05.01618674808Open DOISearch in Google Scholar

23. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007; 107:177-85.10.1016/j.ygyno.2007.07.070275233117822748Open DOISearch in Google Scholar

24. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007; 33:91-5.10.1016/j.ejso.2006.11.01217174517Open DOISearch in Google Scholar